Monopar Therapeutics Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Tables)

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2022

Commitments and Contingencies (Tables)

Maturities Of The Lease Liability

Fiscal Year		Operating Leases
December 31, 2022		$	12,714
December 31, 2023			50,856
December 31, 2024			8,476
Total lease payments			72,046
Less: imputed interest			(3,395	)
Total lease liability as of September 30, 2022		$	68,651

Schdule Of Weighted Average Remaining Lease Term And Discount Rate

		As of September 30,
		2022					2021
Lease term:
Operating leases		1.42 years					-

Discount rate:
Operating lease		6.50%					-

Schdule Of Supplemental Balance Sheet Information

		As of September 30,
		2022				2021
ROU asset - non-current		$	72,889				-
Total ROU asset		$	72,889				-

Operating lease liability - current		$	47,801				-
Operating lease liability - non-current			20,850				-
Total operating lease liabilities		$	68,651				-

Components Of Lease Expense

		Three Months Ended September 30,								Nine Months Ended September 30,
		2022				2021				2022				2021
Total lease costs		$	14,057			$	13,466			$	37,134			$	41,499